CTIS2023-504620-26-00进行中（未招募）1 期
ETNA: Adjuvant pembrolizumab and chemotherapy or surveillance in Early Triple Negative breAst cancer with high stromal tumor-infiltrating lymphocytes (TILs) score - UC-BCG-2213
nicancer0 个研究点目标入组 364 人开始时间: 2024年2月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 364
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed, Women of childbearing potential must agree to use protocol-specified method(s) of contraception for 3 years after patient inclusion. Men subjects who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception during trial treatments and for at least 6 months after the last dose of trial treatments. Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year,, Patients affiliated to the social security system (or equivalent)- France only,, Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up., For cohort 1 : Left ventricular ejection fraction (LVEF) of = 50% as assessed by echocardiogram or cardiac scintigraphy, For cohort 1 : Demonstrate adequate organ function within 7 days of inclusion, Men and women aged = 18 years,, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,, Histologically confirmed and radically removed pT1b/c N0M0 TNBC as defined according to AJCC TNM stage-8th version,, Adequately excised breast cancer: subjects must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy., Have had sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND) for evaluation of pathologic nodal status. Axillary nodal dissection(s) should yield a total of at least six nodes (including the axillary lymph nodes resected at the SLNB plus the lymph nodes collected at the axillary nodal dissection), At least 4 weeks but no more than 12 weeks between definitive breast surgery (or the last surgery with curative intent if additional resection is required for breast cancer) and treatment initiation for cohort 1 and no more than 12 weeks for cohort 2,, Centrally assessed TILs rate from surgical FFPE tumor sample , using an H&E stained diagnostic digital slide, according to the most recent International TILs Working Group guidelines,, Women of childbearing potential have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication for cohort 1 and within 7 days of inclusion for cohort 2,
排除标准
- •History of invasive malignancy = 3 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, Has a known history of active Bacillus Tuberculosis,, Patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment are not eligible,, Pregnant women or breastfeeding or expecting to conceive within the projected duration of the study, from the inclusion visit until the end of the 3 years follow up. Men subjects who engage in heterosexual intercourse and refuse to use protocol-specified method(s) of contraception during trial treatments and for at least 6 months after the last dose of trial treatments,, Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial,, Person deprived of their liberty or under protective custody or guardianship,, Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial., For cohort 1 : Has cardiac dysfunction as defined by any of the following prior to inclusion: - History of NCI-CTCAE v5.0 Grade > 3 symptomatic congestive heart failure or New York Heart Association (NYHA) criteria Class II, - Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease, - Significant symptoms (= Grade 2) relating to left ventricular dysfunction or cardiac ischemia,, For cohort 1 : Has a known hypersensitivity (= Grade 3) to the components of the study therapy or its analogs,, For cohort 1 : Has received a live vaccine or live-attenuated vaccine within 30 days of the first dose of study treatment, For cohort 1 : Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection, Having received prior chemotherapy or targeted therapy within the past 12 months, For cohort 1 : Severe infections within 4 weeks prior to initiation of study treatment, including, hospitalization for complications of infection, bacteremia, or severe pneumonia,, For cohort 1 : Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment; subjects receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection) are eligible,, For cohort 1 : Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during study treatment,, For cohort 1 : Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has a current pneumonitis/interstitial lung disease, For cohort 1 : Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 4 weeks of the first dose of treatment in this current trial., Has a prior history of DCIS and/or LCIS that was treated with any form of systemic, hormonal therapy, or radiotherapy to the ipsilateral breast; subjects who had their DCIS/LCIS treated only with surgery and/or contralateral DCIS treated with radiotherapy are allowed to enter the study, Having received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or with an agent directed to ano
研究者
相似试验
进行中（未招募）
1 期
Pembrolizumab in locally advanced sinonasal carcinoma - NeoPeSinoocally advanced sinonasal carcinomaCTIS2023-505917-25-00Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb28
进行中（未招募）
1 期
Immunotherapy in combination with chemotherapy in small-cell lung cancer.EUCTR2017-004784-12-GRHellenic Cooperative Oncology Group (HeCOG)55
进行中（未招募）
1 期
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosedClassical Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864EUCTR2021-001244-95-PLMerck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.140
进行中（未招募）
1 期
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosedCTIS2022-501615-14-00Merck Sharp & Dohme LLC146
进行中（未招募）
1 期
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosedEUCTR2021-001244-95-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.140